2025
Glucagon-Like Peptide-1 Receptor Agonist Eligibility Among US Adolescents and Young Adults
Chetty A, Sharifi M, Nugent J. Glucagon-Like Peptide-1 Receptor Agonist Eligibility Among US Adolescents and Young Adults. JAMA Pediatrics 2025, 179 PMID: 40758363, PMCID: PMC12322816, DOI: 10.1001/jamapediatrics.2025.2308.Peer-Reviewed Original ResearchThe Impact and Safety of GLP‐1 Agents and Breast Cancer
Parsons K, Montalvo M, Fischbach N, Taylor M, Alfaro S, Lustberg M. The Impact and Safety of GLP‐1 Agents and Breast Cancer. Cancer Medicine 2025, 14: e70932. PMID: 40552446, PMCID: PMC12186097, DOI: 10.1002/cam4.70932.Peer-Reviewed Original ResearchConceptsBreast cancer patientsGLP-1 receptor agonistsBreast cancerBreast cancer-specific mortalityCancer patientsBreast cancer incidenceBreast cancer ratesWeight management interventionsProportion of breast cancer patientsNon-cancer populationObese post-menopausal womenReceptor agonistsBreast cancer outcomesBreast cancer progressionWeight loss interventionWeight management strategiesEffective weight managementGLP-1Quality of lifeAll-Cause MortalityCancer-specific mortalityImprove patient outcomesObesity prevalenceWeb of ScienceCancer incidenceMedications for Weight Loss and MASLD: A National Survey of Hepatology and Gastroenterology Provider Practices, Attitudes, and Knowledge Before Resmetirom.
Im G, Asgharpour A, Aby E, Stine J, Mellinger J, Luther J, Izzy M, Haque L, Lee B, Cotter T, Sherman C, Jophlin L, Goel A, Rice J, Chandna S, Lizaola-Mayo B, Chen P, Singal A, Bansal M. Medications for Weight Loss and MASLD: A National Survey of Hepatology and Gastroenterology Provider Practices, Attitudes, and Knowledge Before Resmetirom. Journal Of Clinical Gastroenterology 2025 PMID: 40549581, DOI: 10.1097/mcg.0000000000002147.Peer-Reviewed Original ResearchWeight loss medicationsGlucagon-like peptide-1Weight lossGastroenterology providersGlucagon-like peptide-1 receptor agonistsPrescribed off-label medicationsPrescribing weight loss medicationsOff-label medicationsFDA-approved medicationsLiver transplant centersOff-label prescribingMedication prescription ratesReceptor agonistsCost/insurance coveragePrescription ratesLiver diseaseSide effectsTransplant centersPeptide-1Steatotic liver diseaseObesity educationBenefit patientsPatientsResmetiromMedicationTirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT‐MMO trial
Lam C, Rodriguez A, Aminian A, Ferrannini E, Heerspink H, Jastreboff A, Laffin L, Pandey A, Ray K, Ridker P, Sanyal A, Yki‐Jarvinen H, Mason D, Strzelecki M, Bartee A, Cui C, Hurt K, Linetzky B, Bunck M, Nissen S. Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT‐MMO trial. Obesity 2025 PMID: 40545827, DOI: 10.1002/oby.24332.Peer-Reviewed Original ResearchSecondary cardiovascular disease preventionCardiovascular disease preventionCardiovascular diseaseGlucagon-like peptide-1 receptor agonistsGlucose-dependent insulinotropic polypeptide receptorPeptide-1 receptor agonistsMultiple cardiovascular risk factorsCardiovascular risk factorsHeart failure eventsNonfatal myocardial infarctionType 2 diabetesReduction of morbidityDisease preventionDouble-blindPrimary endpointReceptor agonistsClinical benefitImprove morbidityObesityCoronary revascularizationRisk factorsOutcome trialsTirzepatideMultiple outcomesSubstantial weight reduction308-OR: Risk of New Cancer Diagnoses with GLP-1 Receptor Agonist, SGLT2 Inhibitor, DPP-4 Inhibitor, and Sulfonylurea Use in Type 2 Diabetes
SKLEPINSKI S, HERRIN J, SINDHU SWARNA K, NEUMILLER J, GALINDO R, UMPIERREZ G, ROSS J, DENG Y, POLLEY E, MICKELSON M, MCCOY R. 308-OR: Risk of New Cancer Diagnoses with GLP-1 Receptor Agonist, SGLT2 Inhibitor, DPP-4 Inhibitor, and Sulfonylurea Use in Type 2 Diabetes. Diabetes 2025, 74 DOI: 10.2337/db25-308-or.Peer-Reviewed Original ResearchDipeptidyl peptidase-4 inhibitorsIncident cancer riskSodium-glucose cotransporter 2 inhibitorsIncident cancerGLP-1RACancer riskHigher risk of incident cancerType 2 diabetesRisk of incident cancerHigh riskReceptor agonistsMedicare fee-for-serviceFemale breast cancerFee-for-serviceGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsGLP-1 receptor agonistsPropensity score inverse probabilityTarget trial emulationModerate CVD riskCox proportional hazards modelsOptumLabs Data WarehousePeptidase-4 inhibitorsIncidence of melanomaAdverse cardiovascular eventsAmycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study
Dahl K, Toubro S, Dey S, Duque do Vale R, Flint A, Gasiorek A, Heydorn A, Jastreboff A, Key C, Petersen S, Vegge A, Adelborg K. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. The Lancet 2025 PMID: 40550231, DOI: 10.1016/s0140-6736(25)01185-7.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsAmylin receptor agonistAdverse eventsGLP-1Receptor agonistsTreatment durationPlasma concentration-time curvePhase 1b/2a studyConcentration-time curveMaximum plasma concentrationEarly-phase studiesClinical Research CentreRandomised controlled studyProportion of discontinuationBaseline bodyweightPart BTolerability profileMaintenance dosePlacebo-ControlledGastrointestinal eventsPrimary endpointSecondary endpointsFull analysisWeight loss propertiesPlasma concentrationsGlucagon-like Peptide-1 receptor agonists for the prevention and treatment of Parkinson’s disease
Lee S, Yin L, Xiao N, Rhee T, Lo H, Wong S, Fox S, Teopiz K, Lam B, Zheng Y, Le G, Mansur R, Rosenblat J, McIntyre R. Glucagon-like Peptide-1 receptor agonists for the prevention and treatment of Parkinson’s disease. CNS Spectrums 2025, 30: e44. PMID: 40485141, DOI: 10.1017/s109285292510031x.Peer-Reviewed Original ResearchConceptsGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsGLP-1RAsCentral nervous systemReceptor agonistsEvidence of clinically meaningful benefitFood and Drug Administration (FDA)-approved treatmentsTreatment-emergent adverse eventsParkinson's diseaseEffects of GLP-1RAsEmergent adverse eventsClinically meaningful benefitFDA-approved treatmentClinical trial evidenceNo current therapyTreatment of Parkinson's diseasePreclinical evidenceAdverse eventsCurrent therapiesMeaningful benefitClinical evidenceFeatures of PDTherapeutic benefitTrial evidenceInsulin resistanceGDF8 and activin A blockade protects against GLP-1–induced muscle loss while enhancing fat loss in obese male mice and non-human primates
Mastaitis J, Gomez D, Raya J, Li D, Min S, Stec M, Kleiner S, McWilliams T, Altarejos J, Murphy A, Yancopoulos G, Sleeman M. GDF8 and activin A blockade protects against GLP-1–induced muscle loss while enhancing fat loss in obese male mice and non-human primates. Nature Communications 2025, 16: 4377. PMID: 40360507, PMCID: PMC12075787, DOI: 10.1038/s41467-025-59485-9.Peer-Reviewed Original ResearchConceptsGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsReceptor agonistsA blockadeGlucagon-like peptide-1 receptor agonist treatmentMuscle lossMuscle massFat lossObese male miceNon-human primatesType II activin receptorTreatment of obesityQuality of weight lossSignificant muscle lossIncrease muscle massEnhanced fat lossAgonist treatmentMale miceMuscle preservationAppetite suppressionActivin AActivin receptorsObese miceCaloric restrictionWeight lossHypothesizing glucagon-like peptide 1 (GLP-1), agonists promote hypodopaminergia, resulting in heightened addictive reward-seeking and altered mood: Breaking the bubble and adding salt to a wound
Blum K, Dennen C, Lewandrowski K, Sharafshah A, Pinhasov A, Bowirrat A, Elman I, Cadet J, Braverman E, Thanos P, Makale M, Baron D, Ashford J, Fuehrlein B, Avena N, Gardner E, Badgaiyan R, Gondré—Lewis M, Modestino E, Khalsa J, Murphy K, Sunder K, Foojan Z, Jafari N, Carney P, Cortes R, Edwards D, Roy A, Smith D, Gold M. Hypothesizing glucagon-like peptide 1 (GLP-1), agonists promote hypodopaminergia, resulting in heightened addictive reward-seeking and altered mood: Breaking the bubble and adding salt to a wound. Medical Hypotheses 2025, 198: 111612. DOI: 10.1016/j.mehy.2025.111612.Peer-Reviewed Original ResearchReceptor agonistsGLP-1 receptor agonistsUse disorderGABA neuronsActivation of VTA GABA neuronsActivity of VTA dopamine neuronsIn vivo fiber photometryAttenuated cocaine seekingVTA dopamine neuronsVTA GABA neuronsReward-seeking behaviorAssociated with increased activityDopaminergic reward pathwayAlcohol use disorderSubstance use disordersGLP-1Cocaine seekingFluorescence in situ hybridizationReward-seekingReward pathwayAntiaddictive propertiesDopamine signalingDopaminergic pathwaysDopamine neuronsFiber photometryEmerging Therapeutics in the Treatment of Substance Use Disorders: A Focus on GLP-1 Receptor Agonists, D3R Antagonists, and CRF Antagonists
Draghmeh K, Fuehrlein B. Emerging Therapeutics in the Treatment of Substance Use Disorders: A Focus on GLP-1 Receptor Agonists, D3R Antagonists, and CRF Antagonists. Journal Of Integrative Neuroscience 2025, 24: 26361. PMID: 40302255, DOI: 10.31083/jin26361.Peer-Reviewed Original ResearchConceptsSubstance use disordersCorticotropin-releasing factorTreatment of substance use disordersCorticotropin-releasing factor antagonistTreating substance use disordersDrug-seeking behaviorDopamine D3 receptorGlucagon-like peptide-1Reduce substance useUse of alcoholAddiction processD3R antagonistsReward modulationRelapse preventionD3 receptorsUse disorderStimulant useSubstance useGlucagon-like peptide-1 receptor agonistsPrevent relapseReceptor agonistsTarget different aspectsSignificant public health challengeAntagonistDisordersOral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial
Marx N, Deanfield J, Mann J, Arechavaleta R, Bain S, Bajaj H, Tanggaard K, Birkenfeld A, Buse J, Davicevic-Elez Z, Desouza C, Emerson S, Engelmann M, Hovingh G, Inzucchi S, Jhund P, Mulvagh S, Pop-Busui R, Poulter N, Rasmussen S, Tu S, McGuire D, Group O. Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial. Circulation 2025, 151: 1639-1650. PMID: 40156843, PMCID: PMC12144549, DOI: 10.1161/circulationaha.125.074545.Peer-Reviewed Original ResearchConceptsOral semaglutideType 2 diabetesAdverse cardiovascular eventsCardiovascular eventsCardiovascular outcomesAdverse cardiovascular events outcomeEffects of oral semaglutidePrimary outcomeMajor adverse cardiovascular events outcomeAdverse event profilePrimary outcome eventNonfatal myocardial infarctionChronic kidney diseaseAtherosclerotic cardiovascular diseaseCardiovascular event outcomesSGLT2i treatmentSGLT2i useReceptor agonistsAdverse eventsPrespecified analysesFollow-upCardiovascular deathRandomized trialsSemaglutideNonfatal strokeOral Health Risks of Transmucosal Buprenorphine: Commentary on Tuan et al. and Zheng et al.
Black A, Becker W. Oral Health Risks of Transmucosal Buprenorphine: Commentary on Tuan et al. and Zheng et al. Journal Of Addiction Medicine 2025 PMID: 40066875, PMCID: PMC12210154, DOI: 10.1097/adm.0000000000001452.Peer-Reviewed Original ResearchOpioid use disorderUse disorderOral health problemsOral health risksPartial mu-opioid receptor agonistBuprenorphine exposureLong-acting injectable buprenorphineMu-opioid receptor agonistDrug AdministrationImprove withdrawal symptomsOral disease developmentOral hygiene practicesGold standard treatmentWithdrawal symptomsDecreasing opioid-related mortalityFood and Drug AdministrationBuprenorphine administrationTransmucosal formulationsOral diseasesReceptor agonistsIntravenous buprenorphineTooth decayAddiction medicineStandard treatmentHealth problemsThe Safety Profile of Pridopidine, a Novel Sigma-1 Receptor Agonist for the Treatment of Huntington’s Disease
Goldberg Y, Navon-Perry L, Cruz-Herranz A, Chen K, Hecker-Barth G, Spiegel K, Cohen Y, Niethammer M, Tan A, Schuring H, Geva M, Hayden M. The Safety Profile of Pridopidine, a Novel Sigma-1 Receptor Agonist for the Treatment of Huntington’s Disease. CNS Drugs 2025, 39: 485-498. PMID: 40055280, PMCID: PMC11982116, DOI: 10.1007/s40263-025-01171-x.Peer-Reviewed Original ResearchSafety profileAdverse eventsAntidopaminergic medicationsOpen-label extension studySigma-1Sigma-1 receptor agonistCytosine-adenine-guaninePlacebo-controlled studySpectrum of disease severityAnalysis of pooled dataTotal functional capacityFirst-in-classRecommended human doseSigma-1 receptorTreatment of Huntington's diseaseUnmet medical needLong-term useDouble-blindReceptor agonistsPridopidineHuman doseSafety signalsEffective treatmentPlaceboExtension studyGlucagon-like peptide-1 receptor agonists but not dipeptidyl peptidase-4 inhibitors reduce alcohol intake
Farokhnia M, Tazare J, Pince C, Bruns N, Gray J, Re V, Fiellin D, Kranzler H, Koob G, Justice A, Vendruscolo L, Rentsch C, Leggio L. Glucagon-like peptide-1 receptor agonists but not dipeptidyl peptidase-4 inhibitors reduce alcohol intake. Journal Of Clinical Investigation 2025, 135: e188314. PMID: 40048376, PMCID: PMC12043080, DOI: 10.1172/jci188314.Peer-Reviewed Original ResearchAlcohol use disorderTreat alcohol use disorderGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsDipeptidyl peptidase-4 inhibitorsPeptidase-4 inhibitorsDPP-4isOperant oral alcohol self-administrationDPP-4iAlcohol intakeOral alcohol self-administrationBinge-like alcohol drinkingBaseline alcohol use disordersReceptor agonistsAlcohol self-administrationAlcohol-dependent ratsReduce alcohol drinkingAlcohol drinkingGLP-1RAAlcohol Use Disorders Identification Test-Consumption (AUDIT-C) scoresReduce alcohol intakeGLP-1RAsImpact of dipeptidyl peptidase-4 inhibitorReverse translational approachBaseline hazardous drinkingA Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research
Yaden D, Graziosi M, Owen A, Agin-Liebes G, Aaronson S, Allen K, Barrett F, Bogenschutz M, Carhart-Harris R, Ching T, Cosimano M, Danforth A, Davis A, Garcia-Romeu A, Griffiths R, Grob C, Gründer G, Gukasyan N, Heinzerling K, Hendricks P, Holze F, Horton D, Johnson M, Kelmendi B, Peck S, Koslowski M, Liechti M, Mertens L, Moreno F, Nayak S, Nicholas C, Preller K, Rieser N, Ross S, Sergi K, Sloshower J, Smigielski L, Stenbæk D, Vollenweider F, Weiss B, Wolff M, Yaden M. A Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research. Psychedelic Medicine 2025, 3: 1-18. PMID: 40351554, PMCID: PMC12060849, DOI: 10.1089/psymed.2024.0019.Peer-Reviewed Original ResearchResearch settingsSerotonin 2A receptor agonistAcute subjective effectsReflexive thematic analysisPsychological safetyPsychedelic treatmentIdentified themesSerotonergic psychedelicsSubjective effectsPsychological supportThematic analysisMedical staffPsychedelic experienceStates of consciousnessFamily historyPsilocybinReceptor agonistsWell-beingPsilocybin studiesDecades of researchPsychedelicsPsychoeducationPotential contraindicationsLevel of riskAnticipated outcomesShort- and long-term glycemic effects of pasireotide in patients with acromegaly: a comprehensive case study with review of literature
Taki Y, Kono T, Matsuda T, Kozu R, Fujimoto M, Sakuma I, Hashimoto N, Horiguchi K, Higuchi Y, Tanaka T. Short- and long-term glycemic effects of pasireotide in patients with acromegaly: a comprehensive case study with review of literature. Endocrine Journal 2025, 72: 421-435. PMID: 39842795, PMCID: PMC11997266, DOI: 10.1507/endocrj.ej24-0548.Peer-Reviewed Original ResearchSomatostatin receptor 5GLP-1RAsContinuous glucose monitoringGrowth hormoneOptimal first-line treatmentGLP-1 receptor agonistsEfficacy of GLP-1RAsMultireceptor somatostatin analogsEffects of pasireotideFirst-line therapyFirst-line treatmentInsulin-like growth factor-1Optimal treatment strategyControlling hormone levelsEarly detectionGrowth factor-1Pasireotide therapyInhibit insulin secretionSomatostatin analogsFirst-lineReceptor agonistsTreatment optionsPasireotideReceptor 5Treatment strategies
2024
The potential of non-psychedelic 5-HT2A agents in the treatment of substance use disorders: a narrative review of the clinical literature
Pulido-Saavedra A, Borelli A, Kitaneh R, Alrafayia M, Jalilian-Khave L, Funaro M, Potenza M, Angarita G. The potential of non-psychedelic 5-HT2A agents in the treatment of substance use disorders: a narrative review of the clinical literature. Expert Opinion On Pharmacotherapy 2024, 26: 133-146. PMID: 39708346, PMCID: PMC11786980, DOI: 10.1080/14656566.2024.2446623.Peer-Reviewed Original ResearchConceptsTreatment of substance use disordersSubstance use disordersTreating substance use disordersPsychedelic agentsNarrative reviewReceptor agonistsClinical literatureReceptor antagonistNovel interventionsClinical evidenceFDA approvalPublic health issueDisordersReceptorsAgonistsTreatmentCravingPositive resultsPsychedelicsAbstinenceReviewed literatureAgentsHealth issuesAntagonistPrimary affinityA systematic review of the use of GLP-1 receptor agonists in surgery
Ihnat J, De Baun H, Carrillo G, Dony A, Mukherjee T, Ayyala H. A systematic review of the use of GLP-1 receptor agonists in surgery. The American Journal Of Surgery 2024, 240: 116119. PMID: 39615284, DOI: 10.1016/j.amjsurg.2024.116119.Peer-Reviewed Original ResearchGLP-1 receptor agonistsGLP-1RAsReceptor agonistsGLP-1Screen preoperative patientsRate of hypoglycemic eventsPotential surgical complicationsDelayed gastric emptyingGLP-1RA useAssociated with improved glycemic controlSystematic reviewNon-bariatric surgeonsSurgical complicationsPeri-operativeGLP-1RABMI thresholdsPre-operativelyPreoperative patientsInsulin useGlycemic controlGastric emptyingHypoglycemic eventsPatientsSurgeryComplicationsPharmacological management of pediatric metabolic dysfunction‐associated steatotic liver disease
Jaoudeh R, Hartmann P, Olson O, Gupta O, Kumar S, Ibrahim S, Fawaz R, Aqul A, Hassan S. Pharmacological management of pediatric metabolic dysfunction‐associated steatotic liver disease. Journal Of Pediatric Gastroenterology And Nutrition 2024, 80: 14-24. PMID: 39526564, DOI: 10.1002/jpn3.12402.Peer-Reviewed Original ResearchGLP-1RABody mass indexLiver diseasePediatric patientsPediatric obesityEfficacy of GLP-1RADisease progressionGlucagon-like peptide-1 receptor agonistsSteatotic liver diseaseManagement of pediatric patientsPeptide-1 receptor agonistsClinical management of pediatric patientsAdverse liver outcomesInduce weight lossLong-term efficacyHepatic manifestation of obesityLiver enzyme levelsAlternative therapeutic strategiesHalting disease progressionManifestation of obesityNonalcoholic fatty liver diseaseChildhood obesity ratesFatty liver diseaseReceptor agonistsLiver transplantationConsensus Report on Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Treatment for Individuals With Type 1 Diabetes Using an Automated Insulin Delivery System
Shah V, Peters A, Umpierrez G, Sherr J, Akturk H, Aleppo G, Bally L, Cengiz E, Cinar A, Dungan K, Fabris C, Jacobs P, Lal R, Mader J, Masharani U, Prahalad P, Schmidt S, Zijlstra E, Ho C, Ayers A, Tian T, Aaron R, Klonoff D. Consensus Report on Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Treatment for Individuals With Type 1 Diabetes Using an Automated Insulin Delivery System. Journal Of Diabetes Science And Technology 2024, 19: 191-216. PMID: 39517127, PMCID: PMC11571606, DOI: 10.1177/19322968241291512.Peer-Reviewed Original ResearchGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsGLP-1RA therapyGLP-1RAGLP-1RAsType 1 diabetesReceptor agonistsAdjunctive therapyAbsence of randomized controlled trialsIncreasing prevalence of obesityUS Food and Drug AdministrationRisk of severe hypoglycemiaEffective adjunctive therapyPrevalence of obesityTreatment of T1DFood and Drug AdministrationRandomized Controlled TrialsDiabetic ketoacidosisAdjunctive treatmentMetabolic outcomesSevere hypoglycemiaAutomated Insulin DeliveryConsensus reportDrug AdministrationTherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply